xv 459 has been researched along with Thrombosis in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hussain, MA; Mousa, SA; Mu, DX | 1 |
Kapil, R; Mousa, SA; Mu, DX | 1 |
Christ, DD; Diamond, S; Gan, L; Mutlib, AE; Nemeth, G; Shockcor, J; Way, R | 1 |
3 other study(ies) available for xv 459 and Thrombosis
Article | Year |
---|---|
Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.
Topics: Administration, Intranasal; Administration, Oral; Amino Acids; Animals; Biological Availability; Carotid Arteries; Dogs; Female; Femoral Artery; Fibrinolytic Agents; Injections, Intravenous; Isoxazoles; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1998 |
Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Topics: Administration, Oral; Amidines; Amino Acids; Animals; Bleeding Time; Disease Models, Animal; Dogs; Electroshock; Female; Femoral Artery; Humans; Injections, Intravenous; Isoxazoles; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1999 |
Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
Topics: Amidines; Amino Acids; Animals; Cardiovascular Agents; Chromatography, High Pressure Liquid; Dogs; Feces; Gas Chromatography-Mass Spectrometry; Humans; Isoxazoles; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thrombosis | 2000 |